2025 Honolulu Marathon
The AFTD-Team is an Official Charity Partner of the 2025 Honolulu Marathon taking place on December 14, 2025! We have 10 guaranteed entries and 10 runners who want those entries, but they need to fundraise $5,000 each first. Please Note: You MUST reach out to the Events Department prior to creating your fundraising page. To join the waitlist for…
Read More2025 BMW Dallas Marathon
Join select AFTD staff and members of the local community as we bring greater FTD awareness to the surrounding Dallas area and raise funds to help people affected by FTD. The AFTD-Team will participate in the 2025 BMW Dallas Marathon on December 13th – 14th. We hope you’ll join us for a weekend of connection and awareness.…
Read More2025 Philadelphia Marathon
Join the AFTD-Team as we bring greater FTD awareness to the surrounding Philadelphia area and raise funds to help people affected by FTD. The AFTD-Team will participate in the Philadelphia Marathon on November 22nd and 23rd 2025, as an Official Charity Partner. We hope you’ll join us for a weekend of connection and awareness. Race distances include:…
Read More2025 TCS NYC Marathon
The AFTD-Team is a recurring Official Charity Partner at the TCS NYC Marathon. If AFTD is invited to return to the 2025 race, we will announce it and start letting those interested on our waitlist know. Runners who are selected for our guaranteed entries will need to fundraise a minimum of $5,000 for this race. To…
Read More15th International Conference on Frontotemporal Dementias in Philadelphia, PA
The 15th International Conference on Frontotemporal Dementias is coming to Philadelphia, Pennsylvania, in October, 2026. To learn more about this conference, please visit the ISFTD website.
Read MoreAviadoBio Announces Completion of Second Cohort in ASPIRE-FTD Trial at AFTD Education Conference
Gene therapy company AviadoBio announced the completion of the second cohort of its phase 1/2 clinical trial of a potential genetic FTD treatment at the 2025 AFTD Annual Education Conference in May. The trial is currently recruiting participants in the U.S. and Europe for a third cohort. Earlier Studies Show AVB-101 Is Well Tolerated in…
Read More
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)